According to Gram Research analysis, people with hereditary fructose intolerance produce fructose internally from glucose digestion, even when strictly avoiding dietary fructose. A 2026 study of 14 HFI patients found their blood fructose levels increased significantly during a glucose tolerance test, and laboratory mice with the genetic defect accumulated fructose in their livers through normal glucose metabolism. This explains why some HFI patients develop liver problems despite perfect dietary compliance, suggesting internal fructose production contributes to the condition alongside dietary sources.
A new study discovered something surprising about hereditary fructose intolerance (HFI), a rare genetic condition where people can’t properly break down fructose. Even when patients strictly avoid eating fructose, their bodies still produce it internally from glucose. Researchers found that both HFI patients and mice with the genetic defect showed fructose building up in their livers during normal glucose digestion. This discovery helps explain why people with HFI sometimes have liver problems even when following their diet carefully. The findings suggest that blocking the body’s internal fructose production pathway might help, though initial tests showed it didn’t completely solve the liver fat problem.
Key Statistics
A 2026 research article studying 14 patients with hereditary fructose intolerance found that their blood fructose levels increased significantly at 30 and 60 minutes after consuming glucose, demonstrating that the body produces fructose internally even without dietary sources.
In a 2026 study of mice with aldolase B deficiency (the genetic cause of hereditary fructose intolerance), an aldose reductase inhibitor drug reduced hepatic fructose levels significantly (P = 0.002), but did not reduce liver fat accumulation, suggesting multiple metabolic pathways contribute to liver damage.
A 2026 analysis using labeled glucose in mice with hereditary fructose intolerance confirmed that the polyol pathway converts glucose into fructose-1-phosphate, explaining how fructose accumulates in the liver despite strict dietary fructose restriction.
The Quick Take
- What they studied: Whether people with hereditary fructose intolerance (HFI) produce fructose inside their own bodies, even when they don’t eat it
- Who participated: 14 patients diagnosed with HFI and 14 healthy people without the condition, plus laboratory mice with and without the genetic defect
- Key finding: People with HFI and mice with the genetic defect produced fructose internally when they digested glucose, even though they weren’t eating fructose. This internal fructose accumulated in the liver.
- What it means for you: If you have HFI, your strict fructose-free diet is still important, but your liver problems may partly come from fructose your body makes itself. This opens new treatment possibilities, though blocking this internal production alone didn’t completely fix liver fat buildup in the study.
The Research Details
Researchers compared 14 patients with hereditary fructose intolerance to 14 healthy control subjects. They gave everyone a glucose tolerance test (a standard medical test where you drink a sugary liquid and doctors measure how your body processes it) and measured fructose levels in their blood at different time points. They also used specially labeled glucose in laboratory mice to track exactly how the body converts glucose into fructose internally. Finally, they tested whether a drug that blocks the enzyme responsible for making fructose could reduce liver fructose levels in mice with the genetic defect.
The study combined human patient data with controlled animal experiments. This two-pronged approach allowed researchers to measure what happens in real patients while also testing potential treatments in a controlled laboratory setting. The mouse experiments lasted 9 days and compared mice receiving the experimental drug to mice receiving a placebo.
Understanding whether internal fructose production contributes to HFI complications is crucial because it changes how doctors think about treating the condition. If the problem were only dietary fructose, a strict diet would solve everything. But if the body makes fructose internally, doctors need to develop new strategies beyond diet alone. This research bridges the gap between what we observe in patients (liver problems despite diet) and what might actually be causing those problems.
This study combined human patient observations with controlled animal experiments, which strengthens the findings. The human sample was relatively small (14 patients), which is typical for rare genetic diseases but limits how broadly we can apply the results. The researchers used sophisticated tracking methods (labeled glucose) to follow exactly how the body converts glucose to fructose. However, the mouse studies used very small groups (4-9 mice per group), which is standard for animal research but means results should be confirmed in larger studies.
What the Results Show
When patients with HFI drank a glucose solution, their blood fructose levels increased significantly at 30 and 60 minutes, just like in healthy people. This was surprising because the patients weren’t eating fructose—their bodies were making it from the glucose they consumed. The same pattern appeared in mice with the genetic defect: when given glucose, their bodies converted it into fructose and accumulated it in their livers.
When researchers used specially labeled glucose to track the conversion, they confirmed that both HFI mice and normal mice were converting glucose into fructose through a pathway called the polyol pathway. This is a normal metabolic process, but in HFI patients, the body can’t break down the fructose it creates, so it accumulates.
When researchers gave HFI mice a drug designed to block fructose production (an aldose reductase inhibitor), the treatment successfully reduced fructose levels in the liver by a significant amount. However, the drug did not reduce the amount of fat accumulating in the liver, which is one of the main health problems in HFI.
The study showed that the polyol pathway—the mechanism that converts glucose to fructose—operates normally in both HFI patients and healthy people. This means the problem isn’t that HFI patients have an overactive fructose-making system; rather, they have a broken fructose-breaking system. The liver fat accumulation in HFI mice appeared to be caused by multiple factors, not just fructose buildup alone. Even when researchers reduced fructose levels, the fat problem persisted, suggesting other metabolic processes contribute to liver damage.
Previous research knew that HFI patients had liver problems despite following strict fructose-free diets, but doctors didn’t fully understand why. This study provides a mechanistic explanation: the body produces fructose internally from normal glucose metabolism. This finding aligns with observations that some HFI patients have persistent liver issues even with perfect dietary compliance. The study advances our understanding by showing this isn’t a failure of the diet but rather a fundamental metabolic problem that diet alone cannot completely address.
The study included only 14 HFI patients, which is a small group. While this is understandable because HFI is rare, it means the findings may not apply equally to all HFI patients. The mouse studies used very small groups (4-9 mice), which is standard for animal research but means results need confirmation in larger studies. The drug treatment in mice lasted only 9 days, so we don’t know if longer treatment would have different effects. The study didn’t test whether combining the drug with other treatments might work better than the drug alone.
The Bottom Line
If you have HFI, continue following your fructose-free diet—this research confirms it’s still essential. However, understand that your liver problems may partly result from fructose your body makes internally, not just dietary sources. Talk with your doctor about monitoring your liver health regularly. New treatments targeting internal fructose production are being researched but aren’t yet available for routine use. This research is preliminary and suggests future directions rather than immediate clinical changes.
This research is most relevant to people with hereditary fructose intolerance and their families, as well as doctors who treat HFI patients. It may also interest researchers studying rare metabolic disorders and liver disease. People without HFI don’t need to change their behavior based on this study, as the internal fructose production process is normal and only problematic when the body can’t break down fructose.
This research doesn’t suggest immediate changes in treatment. The findings point toward future drug development that might take several years to reach patients. In the meantime, HFI patients should expect that strict dietary management remains the primary treatment, though new options may emerge as research progresses.
Frequently Asked Questions
Can people with hereditary fructose intolerance make fructose in their bodies without eating it?
Yes. A 2026 study found that HFI patients produce fructose internally when they digest glucose through a normal metabolic pathway called the polyol pathway. This happens in everyone, but HFI patients can’t break down the fructose their bodies make, so it accumulates in their livers.
Why do some people with hereditary fructose intolerance have liver problems even when following a strict diet?
Internal fructose production contributes to liver damage in HFI. A 2026 study showed that even on a fructose-free diet, HFI patients’ bodies convert glucose into fructose, which accumulates in the liver. This internal source supplements dietary fructose as a cause of liver problems.
Is there a new treatment for hereditary fructose intolerance that blocks internal fructose production?
Researchers tested an aldose reductase inhibitor drug in mice that successfully reduced liver fructose levels, but it didn’t reduce liver fat accumulation. While promising, this treatment is experimental and not yet available for patients. More research is needed.
Should people with hereditary fructose intolerance still follow a fructose-free diet if their bodies make fructose anyway?
Yes, absolutely. A 2026 study confirms that dietary fructose restriction remains essential for HFI patients. While the body produces some fructose internally, avoiding dietary sources still significantly reduces total fructose exposure and liver damage.
How does the body convert glucose into fructose in people with hereditary fructose intolerance?
The polyol pathway, a normal metabolic process, converts glucose into fructose in everyone’s body. A 2026 study using labeled glucose confirmed this pathway operates in HFI patients just like healthy people, but HFI patients lack the enzyme to break down the fructose produced.
Want to Apply This Research?
- If you have HFI, track your daily fructose intake in grams and note any liver-related symptoms (fatigue, abdominal discomfort, jaundice). Record glucose consumption separately to monitor how different carbohydrate sources affect your symptoms, since your body converts glucose to fructose internally.
- Work with your healthcare provider to create a personalized glucose monitoring plan. Since your body produces fructose from glucose, tracking total carbohydrate intake—not just obvious fructose sources—becomes important. Use the app to log meals and identify which carbohydrate sources trigger symptoms.
- Set monthly reminders for liver function blood tests as recommended by your doctor. Track energy levels, digestive symptoms, and any signs of liver stress. Share this data with your healthcare team to help them monitor your condition and adjust treatment as new therapies become available.
This research is preliminary and describes findings in a small patient population (14 people) and animal models. It does not establish new clinical treatment guidelines. People with hereditary fructose intolerance should continue following medical advice from their healthcare providers and maintain strict dietary restrictions. The experimental drug mentioned (aldose reductase inhibitor) is not approved for clinical use and should not be pursued outside of research settings. This article is for educational purposes and should not replace professional medical advice. Consult your doctor before making any changes to HFI management based on this research.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.